THTaizou Hirano

Taizou Hirano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taizou Hirano has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low AHI with elevated T90 as a clinical clue to underlying respiratory impairment in the sleep heart health study

    by Taizou Hirano, Hiromasa Ogawa, Shinya Ohkouchi, Toshiya Irokawa, Hisatoshi Sugiura, Hajime Kurosawa

    Extract The apnoea–hypopnoea index (AHI) remains the dominant metric for classifying sleep-disordered breathing severity, but it captures event frequency, not the depth, duration, or cumulative burden of nocturnal oxygen desaturation. Oxygenation-based metrics, including T90 (percentage of sleep time with SpO2 <90%) and sleep apnoea-specific hypoxic burden, provide cardiopulmonary prognostic information beyond AHI [1–3], suggesting that nocturnal hypoxaemia captures dimensions not reflected by AHI.

  • Open Access

    Keratin-5-positive basal-like epithelial cells associate with forced vital capacity in idiopathic pulmonary fibrosis; a cross-sectional analysis

    by Taizou Hirano, Shinya Ohkouchi, Ryoko Saitou-Koyama, Yoshinori Okada, Hisatoshi Sugiura, Hajime Kurosawa

    Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterised by irreversible loss of lung function from fibrosis and alveolar remodelling. Although antifibrotic therapies have improved outcomes, disease progression remains variable and poorly understood [1]. Recent studies have identified aberrant epithelial remodelling – including expansion of basal-like keratin-5 (KRT5)-positive cells – as a feature of IPF [2, 3]. These cells, typically absent from healthy distal lung, emerge in fibrotic regions in a process termed “bronchiolisation”, where distal alveolar epithelium acquires airway-like features [3–5].


  • Open Access

    Low Secretory Leukocyte Protease Inhibitor (SLPI)-Level Potentiates Alternaria Extract-Induced T-Helper 2 (Th2) Airway Inflammation via the Interleukin-33 (IL-33) Pathway

    by Akira Koarai, Shinya Ohkouchi, Hisatoshi Sugiura, Hajime Kurosawa, Taizou Hirano

    Introduction Serine proteases play a critical role in the augmented release and cleavage of IL-33, leading to the expansion of group 2 innate lymphoid cells (ILC2s) and T-helper 2 (Th2) airway inflammation. However, the protective regulation of protease-dependent interleukin-33 (IL-33) activation remains poorly understood. Therefore, we investigated the role of secretory leukocyte protease inhibitor (SLPI), as a serine protease inhibitor, in this protective regulation and aimed to clarify its contribution to type 2 immunity. Methods We evaluated the role of SLPI in the Alternaria extract-induced expansion of ILC2s and Th2-type airway inflammation via IL-33, using three models: SLPI-deficient mice, an in vivo SLPI knockdown model with shRNA, and an in vitro model utilizing primary human bronchial epithelial cells (HBECs) exposed to Alternaria extract under various conditions, including plasmid transfection. Results We showed that two mouse models of downregulation of SLPI gene expression augmented Alternaria extract-induced release of IL-33 and the expansion of ILC2s, together with Th2 airway inflammation. Furthermore, two treatment models using SLPI KO mice, administration of a serine protease inhibitor, bovine pancreatic trypsin inhibitor, or anti-IL-33 antibody, attenuated Th2 airway inflammation. In two in vitro experiments, SLPI, as a serine protease inhibitor, prevented both the release of IL-33 from HBECs and the cleavage of full-length IL-33 to shorter mature forms by neutrophil elastase. Discussion These findings suggest that SLPI functions as a key serine protease inhibitor in regulating IL-33-mediated type 2 immune responses. Low SLPI levels may contribute to the pathogenesis of asthma by promoting Th2 inflammation, highlighting SLPI as a potential therapeutic target in patients with low SLPI expression.


  • Open Access

    A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining

    by Tomonori Makiguchi, Akira Koarai, Chihiro Inoue, Yayoi Aoyama, Taizo Hirano, Takashi Ohe, Tomohiro Ichikawa, Yutaka Shishikura, Hanae Komuro, Yoko Tsukita, et al.

    Background: Relapsing polychondritis (RPC) is a rare progressive autoimmune disease characterized by inflammation in the cartilage of multiple organs. Tracheobronchial involvement appears in nearly half of RPC patients during the course of their disease and represents the main cause of death. Localized tracheobronchial RPC is much rarer, and the pathogenesis remains unclear. Matrilin-1 is a non-collagenous cartilage matrix protein and has been suggested to be a potent autoantigen that induces the airway disease of RPC in animal models. However, the expression of matrilin-1 in tracheobronchial tissue in human remains unclear. Therefore, we examined the expression of matrilin-1 in the tracheal and auricular tissues in a localized tracheobronchial RPC patient. Case presentation: A 62-year-old man with systemic sclerosis presented with cough and dyspnea on exertion. The lung function test showed an expiratory flow limitation and chest computed tomography showed diffuse thickness from the trachea to the bronchiole. No other tests showed abnormal findings. To evaluate further, bronchoscopy was performed and endobronchial ultrasonography showed thickness in the fourth-marginal echo layer suggesting inflammation of the cartilage. However, the tracheal biopsy showed no specific findings. The subsequent surgical tracheal biopsies showed inflammatory cell infiltration with destruction of the cartilage. Neither auricular nor nasal deformity, except for a tracheobronchial lesion, was detected. Biopsy from the left auricular cartilage also did not show any inflammatory changes. Finally, we diagnosed the patient with localized tracheobronchial RPC. To address the hypothesis that autoimmunity against matrilin-1 is involved in the pathogenesis of localized tracheobronchial RPC, we evaluated the expression level of matrilin-1 in a tracheal and auricular specimen from this patient. Immunohistochemical staining with anti-matrilin-1 antibody showed matrilin-1 in the tracheal but not in the auricular cartilage. Conclusions: We first demonstrated the expression of matrilin-1 in tracheal but not in auricular cartilage in a localized tracheobronchial RPC patient. This result supports the possibility that matrilin-1 is involved in the pathogenesis of localized tracheobronchial RPC. However, this is only one case report and further observations will be needed to confirm this result.


  • Open Access

    Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib

    by Taizou Hirano, Akira Koarai, Tomohiro Ichikawa, Teruyuki Sato, Takashi Ohe, Masakazu Ichinose

    Ceritinib demonstrated a statistically significant effect on the progression-free survival versus chemotherapy in patients with advanced anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) as the first therapy or after previous treatment with crizotinib and one or two prior chemotherapy regimens in global phase 3 studies. However, some serious adverse effects related to ceritinib therapy were reported across these clinical studies. Among them, a grade 3 and 4 increase in hepatobiliary enzymes was one of the common adverse events related to treatment with ceritinib. However, the pathology remains unclear. Previously, increased Interleukin (IL)-18 was observed in both biliary duct disease and liver disease. Therefore, we hypothesized that IL-18 is involved in the pathology of hepatobiliary adverse effects related to treatment with ceritinib and evaluated the serum IL-18. The patient was a 53-year-old Japanese woman that we previously reported as having severe hepatobiliary adverse effects related to ceritinib therapy. Laboratory data, CT and MRI were obtained at each time point. IL-18 was evaluated by ELISA method at each time point. Immunochemical staining of liver tissue was performed as a standard protocol using antibodies against IL-18. Our records showed that the levels of serum IL-18 increased from the early stage of hepatobiliary adverse effects related to the treatment with ceritinib and were became worse with an increase in hepatobiliary enzymes and the progression of imaging abnormalities in the bile duct. Furthermore, IL-18 positive cells were detected in the inflammatory sites around the interlobular bile duct of the liver tissue. Our case report shows that the increase of serum IL-18 had a positive correlation with the progression of severe hepatobiliary adverse effects related to treatment with ceritinib and the involvement of IL-18 in the hepatobiliary inflammation by pathological evaluation. These results suggest that IL-18 could be a useful surrogate marker for the hepatobiliary toxicity of ceritinib. However, this is only one case report and further prospective observations will complement our data in the future.


  • A Case of Pulmonary Eosinophilia as a Rare Presentation of Pulmonary Mucormycosis

    by Taizou Hirano, Mitsuhiro Yamada, Koji Murakami, Kei Sato, Tokiwa Tamai, Hidenori Takahashi, Tatsuma Okazaki, Tsutomu Tamada, Hisatoshi Sugiura, Masakazu Ichinose

    症例は74歳,男性.腹部大動脈破裂術後より発熱・呼吸苦が出現,院内肺炎を疑い,加療を行ったが改善を認めず,抗菌薬不応の肺炎の精査目的に気管支鏡検査を施行した.肺胞洗浄液中,好酸球の増加と糸状菌を認め,好酸球性肺炎と診断.しかし,さらなる加療に反応せず,第39病日に死亡.病理解剖にて侵襲性肺接合菌症の診断が確定した.稀ではあるが,侵襲性肺真菌症と真菌による肺アレルギー性疾患を同時発症することに留意する必要がある.

  • Two cases of pseudo-achalasia with lung cancer: Case report and short literature review

    by Taizou Hirano, Eisaku Miyauchi, Akira Inoue, Ryotaro Igusa, Shigeki Chiba, Kazuhiro Sakamoto, Hisatoshi Sugiura, Toshiaki Kikuchi, Masakazu Ichinose


  • Two cases of endobronchial aspergilloma complicated with primary and metastatic lung cancer: A case report and literature review

    by Taizou Hirano, Mitsuhiro Yamada, Ryotaro Igusa, Atsushi Tanno, Tadahisa Numakura, Kazuhiro Sakamoto, Toshiaki Kikuchi, Masakazu Ichinose